In vivo administration of purified Jurkat-derived interleukin 2 in mice

J. H. Donohue, M. T. Lotze, R. J. Robb, M. Rosenstein, Rita Braziel, E. S. Jaffe, S. A. Rosenberg

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Pure human interleukin 2 (IL-2), produced by the T-cell lymphoma Jurkat, was injected in mice to study the serum half-life, toxicity, and in vivo immunological effects of IL-2. The serum half-life (t( 1/2 )) of Jurkat IL-2 in mice appeared to have two components: (a) a rapid initial phase with t( 1/2 ) of approximately 2 min during which most of the exogenous IL-2 was cleared from the serum; and (b) a second, slower component with t( 1/2 ) of about 9 min. Mice given injections i.p. or i.v. with pure Jurkat IL-2, at doses comparable on a μg/kg basis to contemplated doses for humans, showed no signs of toxicity on the basis of serial measurements of weight, serum liver and kidney chemistries, or histology of lymphoid and vital organs. Jurkat IL-2 had no effect on the rate of growth or survival of mice with an established s.c. methylcholanthrene-induced fibrosarcoma, but Jurkat IL-2 used in conjunction with in vitro-resensitized and IL-2-expanded specific immune splenocytes prolonged survival of mice with disseminated FBL-3 tumor. This survival prolongation was highly significant when compared to treatment with Jurkat IL-2 alone (p =

Original languageEnglish (US)
Pages (from-to)1380-1386
Number of pages7
JournalCancer Research
Volume44
Issue number4
StatePublished - 1984
Externally publishedYes

Fingerprint

Interleukin-2
Serum
Half-Life
Methylcholanthrene
T-Cell Lymphoma
Fibrosarcoma
Histology
Kidney
Weights and Measures
Injections
Survival
Liver
Growth
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Donohue, J. H., Lotze, M. T., Robb, R. J., Rosenstein, M., Braziel, R., Jaffe, E. S., & Rosenberg, S. A. (1984). In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Research, 44(4), 1380-1386.

In vivo administration of purified Jurkat-derived interleukin 2 in mice. / Donohue, J. H.; Lotze, M. T.; Robb, R. J.; Rosenstein, M.; Braziel, Rita; Jaffe, E. S.; Rosenberg, S. A.

In: Cancer Research, Vol. 44, No. 4, 1984, p. 1380-1386.

Research output: Contribution to journalArticle

Donohue, JH, Lotze, MT, Robb, RJ, Rosenstein, M, Braziel, R, Jaffe, ES & Rosenberg, SA 1984, 'In vivo administration of purified Jurkat-derived interleukin 2 in mice', Cancer Research, vol. 44, no. 4, pp. 1380-1386.
Donohue JH, Lotze MT, Robb RJ, Rosenstein M, Braziel R, Jaffe ES et al. In vivo administration of purified Jurkat-derived interleukin 2 in mice. Cancer Research. 1984;44(4):1380-1386.
Donohue, J. H. ; Lotze, M. T. ; Robb, R. J. ; Rosenstein, M. ; Braziel, Rita ; Jaffe, E. S. ; Rosenberg, S. A. / In vivo administration of purified Jurkat-derived interleukin 2 in mice. In: Cancer Research. 1984 ; Vol. 44, No. 4. pp. 1380-1386.
@article{e2ec9c06e5f64bd9930a180fc257d381,
title = "In vivo administration of purified Jurkat-derived interleukin 2 in mice",
abstract = "Pure human interleukin 2 (IL-2), produced by the T-cell lymphoma Jurkat, was injected in mice to study the serum half-life, toxicity, and in vivo immunological effects of IL-2. The serum half-life (t( 1/2 )) of Jurkat IL-2 in mice appeared to have two components: (a) a rapid initial phase with t( 1/2 ) of approximately 2 min during which most of the exogenous IL-2 was cleared from the serum; and (b) a second, slower component with t( 1/2 ) of about 9 min. Mice given injections i.p. or i.v. with pure Jurkat IL-2, at doses comparable on a μg/kg basis to contemplated doses for humans, showed no signs of toxicity on the basis of serial measurements of weight, serum liver and kidney chemistries, or histology of lymphoid and vital organs. Jurkat IL-2 had no effect on the rate of growth or survival of mice with an established s.c. methylcholanthrene-induced fibrosarcoma, but Jurkat IL-2 used in conjunction with in vitro-resensitized and IL-2-expanded specific immune splenocytes prolonged survival of mice with disseminated FBL-3 tumor. This survival prolongation was highly significant when compared to treatment with Jurkat IL-2 alone (p =",
author = "Donohue, {J. H.} and Lotze, {M. T.} and Robb, {R. J.} and M. Rosenstein and Rita Braziel and Jaffe, {E. S.} and Rosenberg, {S. A.}",
year = "1984",
language = "English (US)",
volume = "44",
pages = "1380--1386",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - In vivo administration of purified Jurkat-derived interleukin 2 in mice

AU - Donohue, J. H.

AU - Lotze, M. T.

AU - Robb, R. J.

AU - Rosenstein, M.

AU - Braziel, Rita

AU - Jaffe, E. S.

AU - Rosenberg, S. A.

PY - 1984

Y1 - 1984

N2 - Pure human interleukin 2 (IL-2), produced by the T-cell lymphoma Jurkat, was injected in mice to study the serum half-life, toxicity, and in vivo immunological effects of IL-2. The serum half-life (t( 1/2 )) of Jurkat IL-2 in mice appeared to have two components: (a) a rapid initial phase with t( 1/2 ) of approximately 2 min during which most of the exogenous IL-2 was cleared from the serum; and (b) a second, slower component with t( 1/2 ) of about 9 min. Mice given injections i.p. or i.v. with pure Jurkat IL-2, at doses comparable on a μg/kg basis to contemplated doses for humans, showed no signs of toxicity on the basis of serial measurements of weight, serum liver and kidney chemistries, or histology of lymphoid and vital organs. Jurkat IL-2 had no effect on the rate of growth or survival of mice with an established s.c. methylcholanthrene-induced fibrosarcoma, but Jurkat IL-2 used in conjunction with in vitro-resensitized and IL-2-expanded specific immune splenocytes prolonged survival of mice with disseminated FBL-3 tumor. This survival prolongation was highly significant when compared to treatment with Jurkat IL-2 alone (p =

AB - Pure human interleukin 2 (IL-2), produced by the T-cell lymphoma Jurkat, was injected in mice to study the serum half-life, toxicity, and in vivo immunological effects of IL-2. The serum half-life (t( 1/2 )) of Jurkat IL-2 in mice appeared to have two components: (a) a rapid initial phase with t( 1/2 ) of approximately 2 min during which most of the exogenous IL-2 was cleared from the serum; and (b) a second, slower component with t( 1/2 ) of about 9 min. Mice given injections i.p. or i.v. with pure Jurkat IL-2, at doses comparable on a μg/kg basis to contemplated doses for humans, showed no signs of toxicity on the basis of serial measurements of weight, serum liver and kidney chemistries, or histology of lymphoid and vital organs. Jurkat IL-2 had no effect on the rate of growth or survival of mice with an established s.c. methylcholanthrene-induced fibrosarcoma, but Jurkat IL-2 used in conjunction with in vitro-resensitized and IL-2-expanded specific immune splenocytes prolonged survival of mice with disseminated FBL-3 tumor. This survival prolongation was highly significant when compared to treatment with Jurkat IL-2 alone (p =

UR - http://www.scopus.com/inward/record.url?scp=0021331041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021331041&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 1380

EP - 1386

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -